Biopharma job postings rose 29% in a year, led by Amgen and Regeneron

For all the layoff headlines, there were 29% more biopharma jobs live on BioSpace in October than a year earlier. That figure comes from BioSpace's ranking of the 12 companies hiring most right now, published on 5 November and based on recent job posting volume.

Who is posting

Amgen tops the list, followed by Regeneron, AbbVie, Eli Lilly and Sanofi. Insmed, Novo Nordisk, Legend Biotech, Jazz Pharmaceuticals, Syner-G BioPharma Group, CSL and the United States Pharmacopeia make up the rest.

BioSpace also flagged a second group that is actively hiring: Afton Scientific, Arvinas, Dyne Therapeutics, the Frederick National Laboratory for Cancer Research, Intellia Therapeutics, Lundbeck, ModeX Therapeutics, Recursion and SERB Pharmaceuticals.

Two things stand out. The first is how many of the top names are large, commercial-stage companies, which fits the wider pattern of money moving into launches and manufacturing. The second is the mix lower down: a cell therapy company in Legend, a consultancy in Syner-G and a standards body in USP. Hiring demand is not just coming from drug makers.

A wobble, not a reversal

BioSpace noted slight month-on-month dips in postings over the past few months, but said the trend since the start of 2026 has been generally upward. Last week's issue covered the same story at a local level, with New York postings more than doubling.

The wider jobs market

The official numbers point the same way. The Bureau of Labor Statistics' October employment report, released on 6 November, showed total nonfarm payrolls up 165,000 with unemployment at 4.1%.

Health care added 42,000 jobs, above its average monthly gain of 31,000 over the previous 12 months. Professional, scientific and technical services, which includes contract research and scientific consulting, rose by 33,000. Manufacturing added 19,000 and is up 101,000 since its low in December 2025, though the report does not break out pharmaceutical manufacturing.

None of this is a biopharma-specific measure, and it should not be read as one. It does tell you that the people you want, from clinical staff to scientists to plant operators, have options across neighbouring industries that are also hiring.

What it means in practice

When the largest employers are posting heavily, smaller companies feel it first. Candidates compare offers from household names with strong benefits and clear career ladders. That is not a reason to give up on them, but it is a reason to be sharp on what a smaller company can offer that a big one cannot: scope, speed and visibility.